Brief: Tela Bio Announces U.S. Commercial Launch Of Ovitex® Prs Long-Term Resorbable For Plastic And Reconstructive Surgery
16/08/2023 12:28
TELA Bio Inc TELA.O :
* TELA BIO ANNOUNCES U.S. COMMERCIAL LAUNCH OF OVITEX® PRS
LONG-TERM RESORBABLE FOR PLASTIC AND RECONSTRUCTIVE SURGERY
Source text for Eikon: ID:nGNXbjbcGH
Further company coverage: TELA.O
Recent news on TELA Bio
See all newsTELA Bio Q1 revenue growth beats estimates, loss widens
Brief: TELA Bio Q1 Revenue USD 19.059 Million Vs. IBES Estimate USD 18.6 Million
Brief: Tela Bio Announces Inducement Grants Under Nasdaq Listing Rule
Medical device maker Becton Dickinson sued over alleged hernia mesh monopoly
Brief: TELA Bio Announces Pricing Of $13.0 Million Underwritten Registered Direct Offering Of Common Stock And Pre-Funded Warrants